Understanding structured benefit-risk assessments in pharmaceutical development is crucial for ensuring safe and effective treatments for patients worldwide. Our latest Expert Insights article explores a systematic approach to balancing therapeutic benefits with potential risks, ultimately guiding regulatory decisions and enhancing patient safety. MMS is committed to leveraging structured benefit-risk assessment methodologies to deliver impactful insights and support our Sponsor partners in navigating regulatory pathways effectively. Read the full article for fresh insights: https://hubs.li/Q02Jx7Nd0 #BenefitRiskAssessment #PatientSafety #RegulatoryScience #DrugDevelopment
MMS
Pharmaceutical Manufacturing
Canton, MI 50,582 followers
The difference is in the data.
About us
MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com
- Website
-
https://www.mmsholdings.com
External link for MMS
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Canton, MI
- Type
- Privately Held
- Founded
- 2006
- Specialties
- Clinical Strategy & Execution, Regulatory Affairs and Submissions, Clinical Programming & Biostatistics, Data Management, Clinical Trial Disclosures, Medical Writing, GCP Auditing, clinical research organization, Use of Real World Evidence, Pharmacovigilance & Drug Safety, Quality Control, Quality Assurance, and Data Science
Locations
Employees at MMS
Updates
-
Tomorrow, the SACRA South Africa Career Day Webinar kicks off and Associate Director of Regulatory and Medical Writing Toni-Jone Faihst is presenting! Toni-Jone’s engaging and insightful medical writing discussion will be heard by 600+ registrants, including industry professionals and aspiring students. SACRA is committed to positioning South Africa at the forefront of clinical research, and as a medical writing leader in the region, MMS provides an expert source to explore career paths and gain valuable perspectives. For more details, view the event link: https://hubs.li/Q02Jcyqn0 Leave any questions for Toni-Jone in the comments! 👇 #SACRA #CareerDay #MedicalWriting #ClinicalResearch #Webinar #IndustryInsights #MMS
-
-
Peer-reviewed journal articles play a crucial role in shaping the future of the pharmaceutical industry. Do you agree? Our latest article explores how these publications extend beyond scholarly references to become catalysts for innovation and progress in drug development. Read how peer-reviewed journals are driving innovation: https://hubs.li/Q02JbrNP0 Let's continue to prioritize scientific integrity and collaboration as we work towards a healthier future! #Pharma #DrugDevelopment #Innovation
-
-
In today's pharmaceutical landscape, efficiency and flexibility are paramount. Our Functional Service Provider (FSP) model is designed to meet these demands by offering scalable and adaptable support tailored to your unique needs, providing: 🔹 Expert resources across various functions, from medical writing to PV 🔹 Seamless integration with your existing teams to enhance productivity 🔹 Cost-effective solutions without compromising quality or compliance 🔹 Agility to quickly adapt to changing project requirements and timelines Explore our FSP model here: https://hubs.li/Q02HX3Tj0 #MedicalWriting #Biometrics #Pharmacovigilance #DataScience #Resourcing
-
-
We’re thrilled to share that the MMS team was honored among a prestigious group of prize-winners for our poster presentation at the recent PSI 2024 conference in Amsterdam! Kudos to Japie Lowings and Charl Janse van Rensburg for their insightful poster on the pros and cons of using external data sources in clinical trials. Their detailed work sparked valuable discussions on this crucial topic. To view their poster please click here: https://hubs.li/Q02HM0_V0 At the conference, our #OneMMS team was represented by Lucy Sutton, VP of Account Management and Japie Lowings, Principal Biostatistician. Reflecting on the conference, our team gathered key insights on how evolving biostatistics practices will influence future trial designs and analyses. We’re excited to share how these insights will shape our approach and drive success in clinical trials. Read the blog to gain perspectives on how our MMS biostatistics experts are preparing for change and driving success in trial design and analysis: https://hubs.li/Q02HM13x0 #PSI2024 #Biostatistics #ClinicalTrials #Pharma #Innovation #ExternalData #Estimands #BayesianMethodologies #OneMMS
-
-
Today is World Brain Day! Together, let’s take a moment to recognize the importance of mental health and neurological well-being. At MMS, we are committed to advancing research and innovation in neuroscience to improve lives globally. Thank you to our Sponsors who trust us to do this important work; we are grateful for you! Learn about the therapeutic areas that MMS specializes in here: https://hubs.li/Q02HpYdT0 #WorldBrainDay #Neuroscience #MentalHealth #BrainHealth #ClinicalResearch
-
-
MMS reposted this
Exciting to see details on the Rare Disease Innovation Hub by the FDA. At MMS, we have a long history of supporting Rare Disease data and applications including a probono effort for Ultra-rare diseases that our teams take great pride in. While every data point is important in clinical research, with rare diseases, this is even more crucial and with our Regulatory strategic experience and nimble full-service biometrics, MMS is your go to CRO for rare disease strategy and execution. #DataCRO #Rarediseases #OneMMS
-
MMS welcomes Ben Dudley as Chief Commercial Officer! Ben has over 25 years of experience in the life sciences industry, with a remarkable track record in drug development, sales and customer relationship management, operational leadership, and process optimization. Most recently, Ben served in operational and commercial leadership roles at Parexel, Covance, and AstraZeneca. His expertise in setting visionary strategies aligned with corporate imperatives, commitment to focused growth, and passion for customer relationships make him an invaluable addition to our leadership team. For details on Ben’s role within the MMS executive leadership, please view: https://hubs.li/Q02GVLZn0 #ClinicalResearchOrganization #Pharma #LifeSciences #DataCRO #OneMMS
-
-
In just 1 month, MMS will host the much-anticipated PHUSE SDE in South Africa! The SDE is co-chaired by Pieter Cloete, Senior Manager of Statistical Programming at MMS, and will focus on “The Efficiency Journey: Digital Transformation, Automation and Open Source.” This event will provide a valuable opportunity for biometrics experts and professionals to share their experiences and network with peers in the field. See all of the event details and registration link here: https://hubs.li/Q02Gx-W40 #PHUSE #Biometrics #PHUSESDE2024 #SouthAfrica
-
-
Clinical trials are becoming more complex, with sites spread further across multiple regions, placing a higher burden on Sponsors for pharmacovigilance regulatory compliance. If you are an early-stage drug development Sponsor or work with one, please attend today's webinar or request a copy of the recording to explore what constitutes a compliant pharmacovigilance program, learn of considerations as the new therapy progresses through key milestones, and understand the proper requirements to make informed decisions. It starts at 11AM EST! Last minute registration is still available here: https://hubs.li/Q02G9frG0 #OneMMS #DrugDevelopment #PV #Pharmacovigilance #DrugSafety #Pharmaceuticals
-